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Is Methylphenidate-Induced
Chorea Responsive to
Chlorpromazine?
To the Editor: Involuntary move-
ments are widely reported to occur
with many licit and illicit drugs,
particularly with dopaminergic
agents. Stimulants such as methyl-
phenidate have rarely induced
chorea, mainly after a large dose or
chronic administration.1,2
Case Report
A 6-year-old girl was seen for acute
involuntary movements. She had
psychomotor developmental delay
without a definite diagnosis after
an extensive unrevealing investiga-
tion. As her parents were first-
degree relatives, a genetic basis for
her disease was suspected. Clini-
cally, besides late psychological
and motor acquisitions, she had
discrete macrocephalus, congenital
mild ataxia, and hyperactivity. Oth-
erwise healthy, she was not medi-
cated and had no familial history
of neurological disease. She had the
first 18 mg extended-release meth-
ylphenidate pill that morning and
went to school, where she was
unusually agitated and could not
stay quiet, persistently moving the
neck, arms, and legs as if she was
dancing. Upon examination, she
had persistent choreoathetoid
movements of orofacial muscles,
arms, and legs, with transient dys-
tonic postures of the right arm.
There was no clinical improvement
when she was treated with biperi-
den, Chlorpromazine, 6 mg t.i.d.
(0.25 mg/kg/day), was attempted
at the eighth hour after symptom
onset, with immediate decrease of
the involuntary movements, which
further faded over the next hours
leaving the child in the previous
neurological state.
Discussion
Methylphenidate inhibits dopamine
reuptake by binding to the dopa-
mine transport complex,1 leading
to increased synaptic dopamine
concentration mainly in the stria-
tum.1 This is believed to be the
basis of its ability to induce move-
ment disorders. Nevertheless, this
was reported mainly after chronic
treatment or high doses.1,2 In our
patient, acute chorea was induced
by a single low-dose methylpheni-
date extended-release pill, probably
revealing a dopaminergic system in
its limit of normal function, in
what can be called a brain primed
to dopaminergic challenge.
Chlorpromazine, a widely used
antipsychotic agent, acts by dopa-
minergic receptor blockade.
According to this, the possibility of
counterbalancing methylphenidate
effect on dopamine at the synaptic
level seems attractive. However,
Volkow et al.3 concluded it would
be necessary to block over 80% of
dopamine receptors with a neuro-
leptic before methylphenidate effect
could be attenuated. This suggests
that (a) probably a more rapid
recovery would follow a higher
chlorpromazine dose; (b) the
observed recovery was chlorproma-
zine independent, as the half-life of
this methylphenidate formulation is
12 hours; or (c) chlorpromazine
dose was only sufficient because of
previous low-dose methylphenidate
exposure. We believe that the
immediate response ensuing chlor-
promazine prescription argues in
favor of a specific role for dopa-
mine receptor antagonists in meth-
ylphenidate-induced chorea, justi-
fying further trials in clinical
practice.
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